Antimicrobial Activity of DC-159a, a New Fluoroquinolone, against 1,149 Recently Collected Clinical Isolates

Authors:
Publisher website
Google Scholar
Abstract
The activity of DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth microdilution or agar dilution methods against 1,149 recently collected clinical isolates from five continents. Against pathogens associated with community-acquired respiratory tract infections (CA-RTIs), the MIC 90 s were 0.12 μg/ml for Streptococcus pneumoniae , 0.015 to 0.03 μg/ml for Haemophilus influenzae , 0.03 μg/ml for Moraxella catarrhalis , and 0.12 μg/ml for beta-hemolytic streptococci. Similarly, DC-159a was potent against various types of staphylococci (MIC 90 range, 0.03 to 2 μg/ml), Enterococcus faecalis (MIC 90 , 4 μg/ml), wild-type isolates of the family Enterobacteriaceae (MIC 90 range, 0.06 to 2 μg/ml), wild-type Pseudomonas aeruginosa (MIC 90 , 2 μg/ml), and Acinetobacter spp. (MIC 90 , 0.12 μg/ml). Fluoroquinolone-nonsusceptible organism subsets usually had elevated DC-159a MICs, but the MICs were often two- to fourfold lower than those of levofloxacin and moxifloxacin. In conclusion, DC-159a appears to possess a balanced broad spectrum of activity that exceeds the activities of the currently marketed fluoroquinolones, especially against pathogens that cause CA-RTIs.

This publication has 13 references indexed in Scilit: